— Ascletis is China’s first biotech company which has obtained IND approvals of an oral RdRp inhibitor from both China NMPA and the U.S. FDA — Ascletis has filed multiple patent applications for ASC10 and its use globally. Compared with molnupiravir, ASC10 has a new and differentiated…

Generated by Feedzy